These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 5050745)

  • 21. [Effect of fibrinolysis activation on the peripheral blood circulation in occlusive vascular diseases].
    Bielawiec M; Lukjan H
    Med Monatsschr; 1971 Jul; 25(7):312-4. PubMed ID: 5563915
    [No Abstract]   [Full Text] [Related]  

  • 22. [Contribution to the study of internal temperatures in subjects with arterial diseases with obliterating evolution. I. Effects of sodium nicotinate, theophylline-ethylenediamine and theophylline nicotinate].
    Blasi A; Licciardello M
    Boll Soc Ital Cardiol; 1966; 11(4):1111-5. PubMed ID: 5992024
    [No Abstract]   [Full Text] [Related]  

  • 23. [A method of insulin therapy of chronic obliterating arteriopathies. Clinical results and etiopathogenetic considerations].
    Bonessa C; Cremonini L
    Minerva Med; 1966 Jul; 57(44):2027-40. PubMed ID: 5942708
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experience with Complamin in peripheral circulation disorders].
    Wittenburg H
    Med Monatsschr; 1969 Dec; 23(12):558-61. PubMed ID: 5387170
    [No Abstract]   [Full Text] [Related]  

  • 25. [Research on skin temperature and internal temperature in subjects with obliterating arteriopathy. Action of the association of kallikrein and meso-inositol hexanicotinate].
    Blasi A; Licciardello M
    Clin Ter; 1966 Oct; 39(1):33-8. PubMed ID: 5998855
    [No Abstract]   [Full Text] [Related]  

  • 26. [Medical therapy of obliterating arteriopathies].
    Schwarz D
    Minerva Med; 1969 Oct; 60(87):4335-44. PubMed ID: 4242895
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of peripheral ischemizing arteriopathies with diisopropylammonium dichloroethanoate (Diedì), a drug with action prevalent on respiratory tissue metabolism].
    Maggi GC; Tartara A
    Minerva Cardioangiol; 1965 Jul; 13(7):382-3. PubMed ID: 5838538
    [No Abstract]   [Full Text] [Related]  

  • 28. [Intra-arterial infusion therapy of patients with the ischemic syndrome in thrombo-obliterating diseases of the lower extremities in ambulatory conditions].
    Savel'ev IuS
    Vestn Khir Im I I Grek; 1990 Sep; 145(9):131-4. PubMed ID: 1962927
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of Sadamin on some blood clotting parameters and fibrinolysis in patients with obliterative arteriosclerosis of lower limb arteries].
    Kiersnowska B; Bielawiec M; Lukjan H; Korfel B; Rogowski F; Dowzyk W
    Pol Tyg Lek; 1973 Mar; 28(11):400-3. PubMed ID: 4694796
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapeutic acquisitions on chronic obliterating peripheral arterial diseases of the lower limbs].
    Guagliano G; Bagliani A; Borri P
    Minerva Med; 1976 May; 67(25):1648-55. PubMed ID: 778666
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
    Bagliani A; Borri P; Taborelli R
    Minerva Cardioangiol; 1973 Jun; 21(6):439-52. PubMed ID: 4720185
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of bencyclane in obliterative arterial diseases].
    Kusztos D
    Arzneimittelforschung; 1970 Oct; 20(10):Suppl 10a:1419+. PubMed ID: 5536658
    [No Abstract]   [Full Text] [Related]  

  • 33. The significance of vasodilator therapy in obliterative arterial disease.
    Thulesius O
    Scand J Clin Lab Invest Suppl; 1967; 99():222-4. PubMed ID: 6056925
    [No Abstract]   [Full Text] [Related]  

  • 34. [On the therapeutic activity of hemaseril in treatment of ischemic arteriopathies and phlebopathies].
    Tattoni G; Bigazzi P; Gritta G
    Clin Ter; 1974 Mar; 69(3):225-39. PubMed ID: 4846656
    [No Abstract]   [Full Text] [Related]  

  • 35. [The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy].
    D'Ayala Valva G
    Recenti Prog Med; 1966 Jun; 40(6):XIX-XXXVI. PubMed ID: 6014405
    [No Abstract]   [Full Text] [Related]  

  • 36. [Taurine in the therapy of obliterating arteriopathy of the lower extremities. I. Clinical results in various evolutive phases].
    Zanelli G; Ferrero S; Patrone P
    Minerva Cardioangiol; 1971 Nov; 19(11):605-15. PubMed ID: 5128422
    [No Abstract]   [Full Text] [Related]  

  • 37. [Complamine in obliterating peripheral circulatory disorders].
    Kusztos D; Bereczky M; Fono J
    Med Monatsschr; 1970 Mar; 24(3):127-8. PubMed ID: 5436974
    [No Abstract]   [Full Text] [Related]  

  • 38. [7-(3-(METHYL-OXYETHYLAMINE)-2-OXYPROPYL)-1, 3-DIMETHYL-XANTHINE NICOTINATE IN CHRONIC OBLITERATING ANGIOPATHIES].
    FERNANDEZBLANCO E; DEFERNANDEZBLANCO JF; AGUSTINARZENO J
    Sem Med; 1963 Nov; 123():1733-40. PubMed ID: 14110181
    [No Abstract]   [Full Text] [Related]  

  • 39. [Drug therapy of arterial circulatory disorders with Lioftal].
    Greif S
    Munch Med Wochenschr; 1969 May; 111(18):1055-8. PubMed ID: 5819199
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical evaluation of Provasan].
    Wodniecki J; Wolański A
    Wiad Lek; 1970 Oct; 23(20):1791-3. PubMed ID: 5482235
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.